Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIM-DASA: Dasatinib Dose Optimization in Newly Diagnosed CP-CML
NCT01916785Phase 2Completed
- Sponsor
- Centre Hospitalier de Versailles
- Start
- May 2009
- Primary completion
- Dec 2013
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of dasatinib in chronic myeloid leukemia (CML) (3 arms), sponsored by Centre Hospitalier de Versailles. Primary endpoint: Cumulative rate of significant adverse events at 12 months. Started May 2009; status: completed.
02
Drugs
dasatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01916785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01916785.